Jaguar Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Jaguar Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.51M | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | $11.69M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $9.76M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $11.96M | Mar 24, 2023 |
| FY2022 | Dec 31, 2021 | $4.34M | Mar 24, 2023 |
| FY2020 | Dec 31, 2020 | $9.39M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $5.78M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.42M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $4.36M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $141.5K | Apr 9, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($53.58M) | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | ($38.49M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($41.9K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2022 | ($48.4K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2021 | ($52.6K) | Apr 15, 2025 |
| FY2020 | Dec 31, 2020 | ($33.81M) | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | ($38.54M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($32.15M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($21.97M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($14.73M) | Apr 9, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.91M) | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | ($30.83M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($34.29M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($34.42M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($40.71M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($26.65M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($28.95M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($30.82M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($34.25M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($13.59M) | Apr 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.97M | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | $16.54M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $18.60M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.65M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $15.08M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $6.41M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $5.82M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.15M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $4.27M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $7.21M | Apr 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.69M) | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | ($29.38M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($33.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($33.10M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($34.97M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($15.28M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($20.46M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($22.73M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($9.82M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($14.41M) | Apr 9, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $16.0K | Apr 7, 2026 |
| FY2023 | Dec 31, 2022 | $77.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.0K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $7.0K | Mar 11, 2022 |
| FY2019 | Dec 31, 2018 | $6.5K | Apr 3, 2020 |
| FY2017 | Dec 31, 2016 | $104.2K | Apr 9, 2018 |
| FY2016 | Dec 31, 2015 | $23.3K | Feb 15, 2017 |
| FY2015 | Dec 31, 2014 | $55.1K | Mar 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.32M | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | $53.43M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $50.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $47.45M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $53.27M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $42.84M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $36.41M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $41.04M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $43.63M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $3.56M | Apr 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.01M | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | $44.45M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $45.87M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $48.81M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $41.41M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $25.64M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $15.84M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $26.66M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $26.37M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $6.02M | Apr 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $17.20M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $10.67M | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $5.38M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $17.26M | Apr 3, 2020 |
| FY2018 | Dec 31, 2016 | ($2.45M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2015 | $4.40M | Apr 9, 2018 |
| FY2016 | Dec 31, 2014 | ($8.24M) | Feb 15, 2017 |
| FY2015 | Dec 31, 2013 | ($434.9K) | Mar 29, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $5.21M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $5.21M | Apr 10, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($399.92M) | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | ($346.48M) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | ($308.25M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($266.95M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($219.49M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($166.90M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($133.09M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($94.55M) | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | ($62.40M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($40.44M) | Apr 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $968.0K | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | $8.00M | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | $6.47M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $17.05M | Mar 24, 2023 |
| FY2020 | Dec 31, 2020 | $8.09M | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $3.50M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.57M | Apr 3, 2020 |
| FY2018 | Dec 31, 2017 | $520.7K | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $951.0K | Apr 9, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $6.00M | Mar 29, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | (130) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | (2,678) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (36) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (88) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 11, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (22) | Apr 7, 2026 |
| FY2025 | Dec 31, 2024 | (130) | Apr 7, 2026 |
| FY2024 | Dec 31, 2023 | (2,678) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (36) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (88) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | (3) | Mar 11, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | 14.01M | Feb 15, 2017 |
| FY2016 | Dec 31, 2015 | 8.12M | Feb 15, 2017 |
| FY2015 | Dec 31, 2014 | 2.87M | Mar 29, 2016 |